Cirurgia citorredutora no câncer de ovário: uma revisão integrativa
Ovarian cancer ranks fifth on the list of causes of cancer mortality in women. The most used therapeutic approach for this condition is cytoreductive surgery combined with chemotherapy. This review aims to analyze survival related to cytoreductive surgery in cases of ovarian cancer. This occurred through an integrative review of articles from 2018 to 2022, following the PRISMA criteria, in the PubMed database. In total, 32 articles were found and of these, 18 entered this review. Therefore, cytoreduction followed by platinum/taxane-based chemotherapy is the current standard treatment for ovarian cancer. Survival outcomes are inversely related to initial and residual tumor burden after surgery. It appears that cytoreductive surgery is a viable technique that has been associated with good patient outcomes, including a median survival rate of 53 months.
Authors
- Rodrigo Pederzoli (ORCID: https://orcid.org/0000-0003-1104-3308)
- Beatriz Meneses (ORCID: https://orcid.org/0000-0003-3837-8191)
- Maria Eduarda Rodrigues Peixoto (ORCID: https://orcid.org/0009-0009-1999-2365)
- Isabela Rutkowski (ORCID: https://orcid.org/0000-0003-0781-6881)
- Vitória Donadoni Costa (ORCID: https://orcid.org/0000-0001-7709-615X)
- Gabriela Ferreira De Oliveira (ORCID: https://orcid.org/0009-0000-5459-5562)
- V Pinto (ORCID: https://orcid.org/0009-0004-9002-2103)
Institutions
- Universidade Federal de Minas Gerais (BR)
- Univates (BR)
- Universidade de Ribeirão Preto (BR)
- Universidade Federal do Tocantins (BR)
- Universidade do Tocantins (BR)
- Universidad del Pacífico (PY)
- Centro Universitário São Camilo (BR)
Publication Details
- Journal
- Revista de Medicina
- Published
- 2024-11-04
- DOI
- https://doi.org/10.11606/issn.1679-9836.v103i6e-224140
- Primary Topic
- Hedgehog Signaling Pathway Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00